University of California San Francisco

Publications

  1. Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.
    Sun X, Ocampo AA, Hanna A, Taylor BC, Marshall JL, Steele JA, Axelrod ML, Wescott EC, Opalenik SR, DeMichele A, Esserman LJ, Liu MC, Nanda R, Wolf DM, Brown Swigart L, Hirst GL, van 't Veer LJ, Xu Y, Balko JM
    Sci Transl Med. 2026 Apr 22; 18(846):eaec2358.; 
    PubMed
  2. Author Correction: Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.
    Abbasi AB, Liu KD, Russell DW, Files DC, Thomas KW, Youssef F, Gandotra S, Discacciati A, Lim N, Asare AL, Eklund M, Matthay M, Esserman LJ, I-SPY COVID Investigators
    Commun Med (Lond). 2026 Mar 24; 6(1).; 
    PubMed
  3. WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.
    Fiscalini A, Blum K, Fergus K, Hiatt RA, Naeim A, Kaster A, Scheuner MT, van 't Veer LJ, LaCroix AZ, Borowsky AD, Olopade OI, Park HL, Esserman J, Lancaster R, Heditsian D, Brain S, Lee V, Goodman DL, Ross KS, Wenger N, Parker BA, Madlensky L, Tice JA, Shieh Y, Ziv E, Arasu VA, Anton-Culver H, Kaplan CP, Rhoads KF, Badal K, Hogarth M, Petruse A, Soto IA, Leggat-Barr K, Goodman S, Atamer J, Ryu R, Adduci K, Matthews JB, Eklund M, Athena/WISDOM Network Collaborators and Advocate Partners, Sabacan LP, Esserman L
    NPJ Breast Cancer. 2026 May 24.; 
    PubMed
  4. Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial.
    Fergus KB, Ross KS, Scheuner MT, Blanco AM, Tice JA, Ziv E, Shieh Y, van 't Veer L, Olopade OI, Goodman DL, Tong BS, Harvey H, DeRosa D, Risty L, Silver E, Kaster A, Fiscalini AS, Blum K, Heise R, Sabacan L, Heditsian D, Brain S, Petruse A, Eklund M, Hiatt RA, Borowsky AD, Naeim A, Park HL, LaCroix AZ, Parker BA, Lancaster R, Esserman J, Wenger N, Arasu V, Anton-Culver H, Esserman LJ, Madlensky L
    JAMA Intern Med. 2026 Mar 01; 186(3):344-352.; 
    PubMed
  5. A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.
    Switalla KM, Onishi N, Jones EF, Lawhn-Heath C, Ray KM, Hathi DK, Carmona-Bozo JC, Metanat P, Lopes AJ, Falade IO, Quirarte A, Gottipati S, Guo R, Molina-Vega J, Pullakhandam K, Bareng TJ, Watkins M, Chien AJ, Joe BN, Esserman LJ, Hylton N, Mukhtar RA
    Breast Cancer Res. 2026 Apr 11.; 
    PubMed
  6. Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue.
    Goldhammer N, Bont M, Warhadpande S, Choi M, Cedano J, Greenwood H, Ye J, Schwartz CJ, Alvarado M, Ewing C, Goodwin K, Mukhtar RA, Wong J, Abe SE, Chandler J, Jackson J, Olopade OI, Campbell MJ, Lam A, Park C, Vertido A, van 't Veer LJ, Hylton N, Esserman LJ, Rosenbluth JM
    bioRxiv. 2026 Mar 04.; 
    PubMed
  7. Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, study.
    Files DC, Matthay MA, Chapple AG, Barragan AB, Mabrey L, Gibbs KW, Krall J, Aggarwal NR, Burnham EL, Liu KD, Meyer NJ, Nates JL, Youssef FA, Friedman E, Kett DH, Koff J, Russell DW, Calfee CS, Eklund M, Esserman LJ
    Lancet Respir Med. 2026 May 15.; 
    PubMed
  8. Screening for Breast Cancer-Reply.
    Esserman LJ, Olopade OI, Eklund M
    JAMA. 2026 Apr 06.; 
    PubMed
  9. Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study.
    Shieh Y, Heise RS, Madlensky L, Sabacan LP, Soto IA, Fiscalini AS, Ross K, Goodman D, Blanco A, Brain S, Heditsian DM, Moya J, Fergus KB, Olopade OI, Scheuner MT, Eklund M, Ziv E, Tice JA, van 't Veer L, Esserman LJ, Athena Breast Health Network and WISDOM Study Investigators and Advocate Partners
    JAMA Oncol. 2026 May 31.; 
    PubMed
  10. Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.
    Esserman LJ, Fiscalini AS, Naeim A, Van't Veer LJ, Kaster A, Scheuner MT, LaCroix AZ, Borowsky AD, Anton-Culver H, Olopade OI, Esserman J, Lancaster R, Madlensky L, Blanco AM, Ross KS, Goodman DL, Tong BS, Hogarth M, Heditsian D, Brain S, Lee V, Blum K, Kim MO, Sabacan LP, Fergus KB, Yau C, Park HL, Parker BA, Kaplan C, Rhoads KF, Eder S, Adduci K, Matthews JB, Wenger NS, Shieh Y, Hiatt RA, Ziv E, Tice JA, Eklund M
    JAMA. 2026 03 03; 335(9):763-774.; 
    PubMed